<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03276312</url>
  </required_header>
  <id_info>
    <org_study_id>ADF01</org_study_id>
    <nct_id>NCT03276312</nct_id>
  </id_info>
  <brief_title>Autologous Micro-fragmented Adipose Tissue in the Treatment of Minor Amputations of Diabetic Foot</brief_title>
  <official_title>Local Inoculation of Autologous Micro-fragmented Adipose Tissue in the Treatment of Minor Amputations of Diabetic Foot: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Modena and Reggio Emilia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Modena and Reggio Emilia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled monocentric study on 114 diabetic patients with the aim of
      evaluating the efficacy of the lipofilling with Lipogems速 system in diabetic patients that
      are candidates for a minor amputation in the foot. In particular, it will be evaluated
      whether the lipofilling will be able to shorten the healing times and to reduce the number of
      major amputations, with consequent positive impact on the quality of life. Patients will be
      randomized to the treatment group with Lipogems速 (local injection of autologous
      micro-fractured adipose tissue) or to the control group, thus, treatment according to
      standard clinical practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective of this study is the evaluation of the time of the healing of the lesions
      resulting from minor amputations (digital or forefoot) treated with Lipogems速 technique.

      Secondary objectives are: 1) assessment of the safety of the lipofilling; 2) evaluation of
      the intensity of pain (VAS); 3) assessment of the skin tropism; 4) calculation of the relapse
      rate (defined as the occurrence of local infections, dehiscence and suffering of skin flaps
      that lead to a revision of the amputation stump or amputation at a higher level); 5)
      evaluation of the time of hospitalization and quality of life (QoL).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Healing time</measure>
    <time_frame>6 months</time_frame>
    <description>Healing time after the minor amputation intended as the complete healing of the amputation stump</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: All types of adverse events will be collected</measure>
    <time_frame>6 months</time_frame>
    <description>All types of adverse events will be collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of relapse</measure>
    <time_frame>6 months</time_frame>
    <description>Relapse is intended as revision of the amputation stump or amputation at a higher level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessed using the VAS pain scale</measure>
    <time_frame>6 months</time_frame>
    <description>Pain will be assessed using the VAS pain scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total time of hospitalization</measure>
    <time_frame>6 months</time_frame>
    <description>Hospitalization of the patient will be assessed counting the number of days in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total time of immobility</measure>
    <time_frame>6 months</time_frame>
    <description>Immobility of the patient will be assessed counting the number of bed rest days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life using the SF-36 questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>Assessment of the quality of life (QoL) before surgery and during all the subsequent follow up visits using the SF-36 questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Diabetic Foot</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lipogems - local injection of autologous micro-fragmented adipose tissue</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Routine clinical practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lipogems</intervention_name>
    <description>Lipogems速 is an innovative system that, starting from minimum quantities of autologous lipoaspirate, provides, with a minimal manipulation, a micro-fragmented and non-expanded adipose tissue product</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with diabetes (diabetes mellitus type 1 and type 2) of both sexes over the
             age of 18 years.

          2. Presence of irreversible gangrene digital or localized at forefoot (with RX of the
             foot negative or positive for osteolytic lesions at phalanges and/or metatarsus).

          3. Patients with vascular problems absent or resolved (evaluated with Eco Color Doppler
             and ABI index (Ankle/Brachial Index, that calculates the ratio of the systolic
             pressure measured at the ankle and the systolic pressure in the arm, both measured in
             supine position using wave continue Doppler. If assessable, it has to be greater
             than/equal to 0.7) and pressure index finger/arm TBI (Toe/Brachial Index, if
             assessable, it has to be greater than/equal to 0.6) and/or by the determination of the
             transcutaneous oxygen pressure (TcPO2 that needs to be equal to or greater than
             30mmHg).

        Exclusion Criteria:

          1. Oncological treatments ongoing or previous (past 5 years) and/or neoplastic lesions

          2. Patient under steroid therapy

          3. Active vascular issues
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Silingardi, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baggiovara Hospital, Vascular Surgery department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roberto Silingardi, Prof</last_name>
    <phone>+390593961224</phone>
    <email>r.silingardi@ausl.mo.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giulia Trevisi Borsari, Dr</last_name>
    <email>giuliatrevisiborsari@tiscali.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Modena and Reggio Emilia</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Silingardi, Prof</last_name>
      <phone>+390593961224</phone>
      <email>r.silingardi@ausl.mo.it</email>
    </contact>
    <contact_backup>
      <last_name>Giulia Trevisi Borsari, Dr</last_name>
      <email>giuliatrevisiborsari@tiscali.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2017</study_first_submitted>
  <study_first_submitted_qc>September 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2017</study_first_posted>
  <last_update_submitted>September 7, 2017</last_update_submitted>
  <last_update_submitted_qc>September 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Modena and Reggio Emilia</investigator_affiliation>
    <investigator_full_name>Giulia Trevisi Borsari</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Lipogems</keyword>
  <keyword>ASCs</keyword>
  <keyword>Lipofilling</keyword>
  <keyword>diabetic foot</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

